Efficacy and Safety of Adalimumab in Noninfectious Uveitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Overview of attention for article published in Frontiers in Pharmacology, April 2021

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (58th percentile)
Good Attention Score compared to outputs of the same age and source (77th percentile)

Mentioned by

policy: 1 policy source

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 22 Mendeley

Summary Policy documents Dimensions citations

So far, Altmetric has seen 2 policy documents that reference this research output.

Adalimumab for the Treatment of Pediatric Populations With Non-Infectious Uveitis

Cited by Canadian Agency for Drugs and Technologies in Health on 04 Mar 2022

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Adalimumab for the Treatment of Adults With Non-Infectious Uveitis

Cited by Canadian Agency for Drugs and Technologies in Health on 19 Jan 2022

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.